MXPA04005265A - Uso de derivados del acido 4-oxobutanoico para el tratamiento contra inflamacion. - Google Patents

Uso de derivados del acido 4-oxobutanoico para el tratamiento contra inflamacion.

Info

Publication number
MXPA04005265A
MXPA04005265A MXPA04005265A MXPA04005265A MXPA04005265A MX PA04005265 A MXPA04005265 A MX PA04005265A MX PA04005265 A MXPA04005265 A MX PA04005265A MX PA04005265 A MXPA04005265 A MX PA04005265A MX PA04005265 A MXPA04005265 A MX PA04005265A
Authority
MX
Mexico
Prior art keywords
inflammation
oxobutanoic acid
treatment
acid derivatives
oxobutanoic
Prior art date
Application number
MXPA04005265A
Other languages
English (en)
Inventor
Maizeray Philippe
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA04005265A publication Critical patent/MXPA04005265A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se relaciona con el uso del derivado del acido 4-oxobutanoico para la preparacion de una composicion farmaceutica para el tratamiento contra inflamaciones.
MXPA04005265A 2001-12-03 2002-11-06 Uso de derivados del acido 4-oxobutanoico para el tratamiento contra inflamacion. MXPA04005265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0115601A FR2832925B1 (fr) 2001-12-03 2001-12-03 Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
PCT/EP2002/012357 WO2003047561A1 (en) 2001-12-03 2002-11-06 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation

Publications (1)

Publication Number Publication Date
MXPA04005265A true MXPA04005265A (es) 2004-10-11

Family

ID=8870049

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005265A MXPA04005265A (es) 2001-12-03 2002-11-06 Uso de derivados del acido 4-oxobutanoico para el tratamiento contra inflamacion.

Country Status (19)

Country Link
US (1) US7897644B2 (es)
EP (1) EP1450780B1 (es)
JP (1) JP2005511654A (es)
KR (1) KR20050043728A (es)
CN (1) CN1599604A (es)
AT (1) ATE355834T1 (es)
AU (1) AU2002342883B2 (es)
BR (1) BR0214644A (es)
CA (1) CA2468910C (es)
DE (1) DE60218726T2 (es)
ES (1) ES2280589T3 (es)
FR (1) FR2832925B1 (es)
HU (1) HUP0402242A3 (es)
MX (1) MXPA04005265A (es)
PL (1) PL369845A1 (es)
RU (1) RU2004120557A (es)
TW (1) TW200300670A (es)
WO (1) WO2003047561A1 (es)
ZA (1) ZA200405246B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2707585A1 (en) * 2007-12-03 2009-06-11 Merck Patent Gmbh Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
JPS59144717A (ja) * 1983-02-07 1984-08-18 Microbial Chem Res Found 鎮痛剤
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
HRP970247B1 (en) * 1996-05-15 2002-02-28 Bayer Ag Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
FR2777566B1 (fr) * 1998-04-15 2003-02-21 Synthelabo Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
US6060250A (en) * 1998-06-30 2000-05-09 Incyte Pharmaceuticals, Inc. Human transferases
WO2000006560A1 (en) * 1998-07-30 2000-02-10 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
FR2793411B1 (fr) * 1999-05-11 2001-06-29 Synthelabo Utilisation de derives de l'acide succinique pour obtenir un medicament destine au traitement de l'inflammation
WO2001062295A1 (fr) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Medicaments contenant des ingredients actifs combines

Also Published As

Publication number Publication date
FR2832925B1 (fr) 2006-07-14
FR2832925A1 (fr) 2003-06-06
TW200300670A (en) 2003-06-16
ATE355834T1 (de) 2007-03-15
KR20050043728A (ko) 2005-05-11
JP2005511654A (ja) 2005-04-28
HUP0402242A2 (hu) 2005-02-28
US7897644B2 (en) 2011-03-01
EP1450780B1 (en) 2007-03-07
DE60218726T2 (de) 2007-11-15
US20050014768A1 (en) 2005-01-20
CA2468910C (en) 2012-01-03
EP1450780A1 (en) 2004-09-01
ZA200405246B (en) 2005-06-24
CN1599604A (zh) 2005-03-23
PL369845A1 (en) 2005-05-02
WO2003047561A1 (en) 2003-06-12
RU2004120557A (ru) 2005-05-10
ES2280589T3 (es) 2007-09-16
HUP0402242A3 (en) 2006-01-30
CA2468910A1 (en) 2003-06-12
BR0214644A (pt) 2004-11-03
DE60218726D1 (de) 2007-04-19
AU2002342883B2 (en) 2007-11-29
AU2002342883A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
MY143795A (en) Tetrahydropyridoindole derivatives
ZA200600579B (en) Piperazine derivatives and methods of use
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
PL1638582T3 (pl) Zastosowanie kwasu hialuronowego do wytwarzania środków do leczenia nawracających aft w jamie ustnej
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
MXPA04005265A (es) Uso de derivados del acido 4-oxobutanoico para el tratamiento contra inflamacion.
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
HK1050203A1 (en) Novel fusidic acid derivatives.
EP1232748A4 (en) SUBSTITUTED NITROBENZENE-LIKE DERIVATIVE PRODUCT AS A MEDICINAL PRODUCT OR OTHER EFFICIENT PRODUCTS
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
MXPA04006269A (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.